Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailor-made ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals.

Syngene’s unique business model allows us to offer R&D services that are flexible and are designed to suit our client’s needs. Starting with a single service (component play), our client engagement gradually leads to an expanded  scope of services (cluster play) and eventually into an integrated play, where we engage across multiple platforms, including setting up Dedicated Centers.

The Dedicated Centers involve long-term strategic collaborations, usually for five year periods  or longer. As part of these long- term collaborations, Syngene sets up a dedicated, customised and ring-fenced infrastructure, in line with our client’s requirements. These Dedicated Centers are generally multi-disciplinary, full time equivalent (FTE)based engagements that support a wide array of integrated R&D requirements of our clients.

Most Dedicated Centers have client staff co-located in the Dedicated Center premises, thereby creating an ideal collaborative environment with real-time and continuous exchange of ideas that fosters creativity and learning for all stakeholders

Biocon Bristol Myers Squibb research and development center (BBRC)

Syngene has been closely associated with Bristol Myers Squibb (BMS) since 1998. In 2007, Syngene set up BBRC, a dedicated research facility for BMS to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development.

Since its inception, BBRC has produced 10 drug candidates for further studies, and has also helped BMS reduce the time and costs associated with advancing new compounds to first-in-human studies. One drug candidate currently in clinical trials, was discovered at BBRC, and early nonclinical development work done at BBRC has enabled most of BMS’s small molecule assets to advance to later stages of development over the last five years.

This facility is the largest research and development center for BMS outside the United States and Europe. It  houses ~600 scientists and is spread across  more than ~200,000 sq ft of dedicated laboratory and office space in Syngene’s Bengaluru campus

Baxter global research center (BGRC)

Syngene and Baxter International Inc., a leading global pharmaceutical company, have collaborated to establish the Baxter global research center (BGRC) at Syngene’s Bangalore premises. This Dedicated Center, supports Baxter in the research and development of medical products and devices to serve patients around the world.

A team of over 200 multidisciplinary Syngene scientists work closely with Baxter scientists on a wide array of R&D activities, centred on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy. The scale and scope of activities signal the strategic nature of the collaboration, and reflect Syngene’s capabilities to offer broad-based, complementary and integrated development services.

Syngene Amgen research and development center (SARC)

Syngene Amgen research and development center (SARC) is a dedicated multi-disciplinary drug discovery and development center set up for Amgen Inc. in Bengaluru. SARC has been customized to Amgen’s requirements and complies with the highest regulatory standards. It is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and “green” chemistry.

Initially setup with a lab space of 25,000 sq. ft and a team of around 100 scientists, it was subsequently expanded to more than 60,000 sq. ft. of dedicated lab space with a team of more than  170 scientists. This scientific team works closely with Amgen’s global R&D team on various projects spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development.

Testimonials

“Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials. We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.”
Read full press release

Amgen is pleased with the success of the long-standing collaboration with Syngene that has contributed to the advancement of a number of molecules into clinical trials. We look forward to continuing to work together with the shared goal of addressing serious disease for patients in need.
Read full press release
Margaret Chu-Moyer, Ph.D
Vice President of Research and Head of Chemistry, Characterization & Technology at Amgen
We greatly value our collaboration with Syngene International and are proud to extend and expand our work together. The dedicated facilities and scientific team at Syngene play an important role in helping us realize our vision to transform patients’ lives through science.
Read full press release
Gregory Vite, Ph.D
Senior Vice President, Small Molecule Drug Discovery, Bristol Myers Squibb

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy, Cookies Policy and .

To view or email, Please share your details view

To download, Please share your details